Skip to main content
Shanghai Rightongene Biotechnology Co., Ltd. logo

Shanghai Rightongene Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 688217 ISIN · CNE100005212 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 629 across all filing types
Latest filing 2026-04-10 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688217

About Shanghai Rightongene Biotechnology Co., Ltd.

https://www.rightongene.com/

Shanghai Rightongene Biotechnology Co., Ltd. specializes in the development, production, and distribution of molecular diagnostic reagents and instruments. The company focuses on precision medicine, particularly within the fields of oncology and hematology. Its product portfolio encompasses diagnostic kits based on multiple technology platforms, including PCR, Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), and digital PCR. Rightongene provides comprehensive solutions for the early screening, diagnosis, treatment monitoring, and prognosis of leukemia and various solid tumors. The company serves medical institutions and clinical laboratories, offering specialized tools for companion diagnostics and personalized treatment planning. By integrating advanced molecular biology techniques, Rightongene facilitates high-sensitivity and high-specificity diagnostic testing to support clinical decision-making.

Recent filings

Filing Released Lang Actions
睿昂基因关于2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Shanghai Rui'ang Gene Technology Co., Ltd. regarding the 2025 profit distribution plan. It details that the company will not distribute dividends or issue bonus shares for the year 2025, citing financial results and strategic considerations. The document includes specifics about the profit distribution proposal, board approval, and risk warnings. It is a formal announcement about the company's dividend policy and profit allocation for the fiscal year 2025, not a full financial report or earnings release. This fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related shareholder information. The document length is short (1925 characters), and it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is DIV with high confidence.
2026-04-10 Chinese
睿昂基因关于召开2025年年度股东会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2025 Annual General Meeting (AGM) of Shanghai Rightongene Technology Co., Ltd., including details such as meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and procedural information related to the AGM. The document length is 3374 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2026-04-10 Chinese
睿昂基因董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors. It references regulatory guidelines about independent directors and confirms their compliance and independence. There is no financial data, no report publication, no voting results, no management changes, or other typical report content. This is a governance-related disclosure about board members' independence, fitting the category of Governance Information (CGR). The document length is short but contains substantive governance content, not just an announcement or certification.
2026-04-10 Chinese
睿昂基因关于2026年度董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2026 remuneration scheme for the company's directors and senior management. It details the salary standards, applicable period, and decision-making procedures related to the compensation plan. There is no financial data, audit information, or report content. The document is a formal announcement of remuneration information for executives and directors, matching the description of Remuneration Information filings.
2026-04-10 Chinese
睿昂基因关于使用部分暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shanghai Rui'ang Gene Technology Co., Ltd. regarding the use of temporarily idle own funds for cash management. It details the investment amount, types of investment products, risk analysis, and board approval. The document is an announcement about financing/cash management activities rather than a financial report or earnings release. It does not contain financial statements or detailed financial data. The content fits best under Capital/Financing Update (CAP) as it relates to the company's cash management and investment of idle funds.
2026-04-10 Chinese
控股股东和实际控制人行为规范（2026年4月）
Governance Information Classification · 95% confidence The document is a detailed set of behavioral norms and regulatory compliance guidelines for controlling shareholders and actual controllers of a listed company, Shanghai Rui'ang Gene Technology Co., Ltd. It references various laws, stock exchange rules, and governance principles. The content focuses on shareholder conduct, disclosure obligations, independence of the company, and control transfer procedures. It is not a financial report, earnings release, or management discussion. It is a governance-related document outlining internal rules and compliance standards for controlling shareholders and actual controllers. Therefore, it fits best under Governance Information (CGR). The document length (8993 characters) and detailed regulatory content support this classification.
2026-04-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.